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Each year when I attend the American
Society of Human Genetics meeting, I
stroll up and down the vendor exhibits to
see what’s new, and, at the most recent
meeting, I noticed one booth that stopped
me in my tracks. The company was
Complete Genomics, and I asked the rep
about the cost of sequencing small stretch-
es of the genome for a project in the lab.
She told me they only do ‘‘complete’’
sequencing—full human genome sequenc-
ing. ‘‘That’s why it’s called ‘Complete’,’’
she added. OK, I get it—so how much
does it cost? ‘‘$20,000 per sample if you
order sequence for eight samples.’’
Figuring that anybody who can produce
accurate full sequence for that kind of
money has to have a clever idea, I looked
at the exhibit materials more closely. Part
of their success comes from employing
‘‘rolling circle’’ replication to amplify a
small circular piece of genomic DNA that
is interrupted by four adapters. The long,
single-stranded DNA that spools off col-
lapses in on itself by base-pairing of
separated, inverted repeats lying in the
adapters, as I later learned, forming a tight
and highly charged ‘‘DNA nanoball.’’
These nanoballs can be uniformly distrib-
uted onto a prepared grid, and the high
concentration of target sequence allows for
very quick and cost-effective imaging. The
four adapter sequences then serve as the
anchors for sequencing—not by enzymatic
extension, but rather by sequential hy-
bridization and ligation of pairs of oligo-
nucleotides for each base position.
The exhibit drew out my inner geek, and
I wanted to learn more. The rep pointed
me in the direction of the inventor and
company co-founder, Radoje Drmanac
(Image 1), informally called ‘‘Rade,’’ who
was deep in conversation with someone
else, so I moved on. A few months later, I
was prompted by his first-author publica-
tion in Science reporting a US$4,000 ge-
nome to delve a little deeper. I discovered
that Rade’s scientific career has been
driven by his ambition to sequence human
genomic DNA using oligonucleotides. In
1988, while still a graduate student in his
native Serbia (Yugoslavia at the time), he
published his first idea, dubbed ‘‘sequenc-
ing by hybridization’’ (SBH), in Genomics
and followed that up with a publication in
1990 about doing PCR in emulsion to
produce abundant template. After working
at Argonne Laboratories and forming two
prior companies, he co-founded Complete
Genomics, finally bringing to fruition his
goal for efficient sequencing of the human
genome.
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Image 1. Radoje Drmanac.
doi:10.1371/journal.pgen.1001049.g001
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vision, tenacity, and spirit of invention that
would make for a good interview. In late
March, I drove through what I hoped
were the final rains of the Bay Area wet
season (they weren’t!), to meet him at
Complete Genomics in Mountain View,
just past the colorful Google campus.
Drmanac: You probably want to
know how to pronounce my name.
Gitschier: Yes!
Drmanac: I can misspell it for you, so
you can pronounce it. It’s like D-E-R-M-
A-N-A-T-S. Two mutations.
Gitschier: Normally when I interview
someone, I like to start with a little
biographical background and work my
way up, but in this case, I want to do the
opposite. Let’s start with where we are
now, and in the course of that, we’ll get
some background. And then we’ll go back
a little deeper.
Drmanac: That’s much better. I’m old
enough that you’ll never come to the
present if you start from Yugoslavia!
Gitschier: Well, you’re younger than I
am! Let’s start by educating me about the
technology that Complete Genomics is
using; I want to make sure I understand it.
First, making the template for the
nanoballs—you start with fragmented
human genomic DNA, then add some
half adapters that ligate to the ends of the
fragments and to each other [forming a
closed circle with the fragment ends—the
‘‘mate pairs’’—separated by ‘‘adapter 1’’].
Then, you add a Type II restriction
enzyme that recognizes a sequence in the
adapter and cuts within the genomic insert
somewhere nearby.
Drmanac: Yes, the first one we used
cuts about 13 bases away. But there are
others that cut 25 bases away.
Gitschier: It must cut in only one
direction.
Drmanac: We have [recognition] sites
[in adapter 1] for it to cut in both
directions, but one site is methylated and
the insert is methylated, so only one site
can be recognized. After we make the first
cut and stick in the second adapter
[adapter 2], we use a few cycles of PCR
to remove the methylation.
Gitschier: Cool.
Drmanac: Just DNA engineering.
Then, we methylate everything again
except this site [the other site in adapter
1] because we keep this single stranded.
Then, when you close the circle, you form
the new unmethylated site, going in the
opposite direction.
Gitschier: And I take it that it’s the
same restriction recognition site, so you
make another cut in the opposite direction
13 bases away from the first adapter.
Drmanac: Correct. There aren’t that
many good restriction enzymes that do
this, so we use the same one. So that is
adapter 3 now [that is inserted]. And
adapter 4 is quite easy. A recognition site
is present in both adapter 2 and 3 and [the
enzyme] cuts 25 bases away from each,
and we remove the 400 bases that we
don’t need and replace that with adapter
4. Quite simple on paper! But it took
several exceptionally talented scientists a
few years to implement.
Gitschier: OK, so now you have a
small circle of human genomic DNA with
four adapters inserted. Adapter 1 separates
the two mate-pair sequences, adapter 4
replaces most of the genomic DNA in
between, and adapters 2 and 3 provide
additional ‘‘anchor’’ sites in the mate-pair
sequences to allow you to extract more
sequence information. And you figure out
what these bases are by oligonucleotide
hybridization.
But before we talk hybridization, we
need to talk about how this template is
amplified into DNA nanoballs—I love
these things.
Drmanac: Yeah—it’s the old famous
W29 enzyme from 20 years ago. In 1989,
Blanco et al. showed they could amplify
M13 plasmids. It has very strong displace-
ment activity, and it is highly processive. It
goes up to 100 kb without stopping. So
that was all known.
You know, my whole life I’ve just used
what is available—in new combinations
and with some modifications—to change
the meaning or purpose of existing
discoveries. So this was one example.
You get this concatemer of 250 bases
and you can make 500 copies.
Gitschier: So this long concatemer
allows you to have this very strong signal
down the road.
Drmanac: Correct. Everybody is now
trying to do single molecule sequencing,
but what we are doing is as simple as you
can get and you don’t have to worry about
single molecule detection, which is costly
and error-prone. We are trying to avoid
those two problems. I think we are right,
at least for now, because the limiting factor
is the imaging step.
Gitschier: So you can do your imag-
ing faster.
Drmanac: Yeah, short exposures. We
can use the nanoballs to make a perfect
grid whereas everybody else is using
random positions [of the template DNA].
The perfect grid allows us to do the most
efficient imaging. You can align the CCD
pixels to the nanoballs. We are going
down to one pixel per nanoball; today we
use two pixels per nanoball to be cautious.
Gitschier: And that’s because before
you put the nanoballs on there, you set up
a grid so that each…
Drmanac: …active site matches the
size of the nanoball. When it is compact,
it’s about 200 nM. It has a strong negative
charge, because it’s a small particle with
,100,000 negative phosphate groups, so
the nanoballs repel each other. So in
solution, there is no entanglement; they
are forcing each other out to be in perfect
separation.
Gitschier: So how does the nanoball
form in the first place with so much
negative charge—why don’t they stretch
out?
Drmanac: We put palindromes of,
say, 7 As and 7 Ts—not adjacent—into
the adapters. When it starts out, it is
single-stranded DNA and hybridizes to
itself. Since it’s single-stranded, it’s flexible
and easy to make into a ball. And we
intentionally made its stability borderline
so the palindromes would pair on and
off—the first binding with the second
initially, but eventually the first binds with
the tenth copy, so it forms a 3-D structure.
Gitschier: And you can regulate that
by the temperature or…
Drmanac: …with the size of the
palindrome and the reaction conditions.
It’s really nanoengineering. Very simple,
but it works.
The other interesting thing about this
circle: it has more synthetic DNA [with the
four adapters] than genomic DNA. So
there is no GC bias between nanoballs
because most of the DNA is shared. That’s
why making the nanoballs is so reproduc-
ible and the size is so consistent. And if you
look at the surface, there is 10 times as
much DNA per unit surface area than you
can get with a bridge PCR amplification.
Gitschier: And it’s already single-
stranded, so you’re all ready to go for the
hybridization.
Drmanac: It’s pretty simple with
almost no disadvantages.
Gitschier: How was the idea for a
DNA nanoball generated?
Drmanac: Matt Callow, a scientist
from my group, thought of it. We got a
Biodefense grant to develop this genomic
array-based sequencing using ligase, and
we tried all kinds of ways to do amplifi-
cation. Matt came one day and said, ‘‘We
can use this old concept of rolling circle
replication.’’ Ah, this is great because you
don’t need oil [for an emulsion PCR step].
In situ amplification on a surface is always
problematic. I expanded on that idea to
add the palindromes, and we played with
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DNA will create a particle in solution. We
can match the size of the particle with the
size of the spots on the array to assure a
single DNA particle per spot. Patterned
DNA nanoarrays are critical for our
success.
Gitschier: What about using the type
II enzyme and the adaptors?
Drmanac: I realized that with mate
pairs, you don’t need much of the
sequence—even 20 bases is enough. But
ligase doesn’t allow you more than about
five, so having extra adapters, which are
inserted through the use of type II
enzymes, provides us with extra stepping
stones for ligase. And this will provide us
with enough sequence data to analyze a
complete human genome.
There is a paper that George Church
published in Science in 2005, where he used
a similar process, without the inserted
adapters. And he read 13 bases on each
mate pair, and that was good for sequenc-
ing E. coli, but it was not good enough for
humans. So that was a simple, but critical
element.
Gitschier: Now we’re going to get
to the sequencing by [oligonucleotide]
hybridization.
Drmanac: That’s quite simple.
Gitschier: Well, I understand it a bit,
but not completely. You read two sets of
genomic sequence adjacent to adapter 1
that are each 13–15 bases in length and
two sets of sequence adjacent to adapter 4
that are each 25 bases in length.
Drmanac: Correct. That is for now;
we will go up to all being 25 bases in
length. But let’s start with the first five
bases. There is an anchor oligo that
matches the end of the adapter. Then the
sequencing oligo, which is always nine
bases. Only one of the bases is informa-
tive, everything else is degenerate, and
we read only five bases in each of them.
You have a pool of probes, with one base
being queried and the other eight
positions being degenerate, meaning
you have 65,000 [4
8] different sequences
for each of the four bases at each
position.
We pipette this mixture over the array
and then we ligate. Anything that can be
ligated will ligate. The first five bases are
all that matter—for ligase and for us—
because we never read beyond the fifth
base. We put the informative bases only in
the first five positions, because ligase has
good proofreading up to five bases. We
make them nine bases total in length only
for the footprint of the ligase.
Gitschier: But I don’t understand how
you keep track of which oligo is which.
Drmanac: It’s all about this one
informative base. If the DNA has C at
this position, the probe with a G there will
ligate, and it is labeled with a specific dye.
Gitschier: Well, I understand that, but
there are going to be a lot of molecules in
the collection that have a G there—in fact
J of them, and how do you know which
one…
Drmanac: It doesn’t matter! Because
we don’t read anything else.
Gitschier: OK, I get it now!
You are querying only one base at a
time, not the whole stretch of five bases.
You do repeated rounds of querying. So
the first round you have a pool of oligos,
where everything in the first position with
a G, say, is tagged with one dye, and A
another dye, etc. Then you must wash
everything off and you go through with a
new set of 256,000 probes, 65,000 with a
G in the second position, etc., and you do
that hybridization and ligation, wash that
off, etc.
Drmanac: Exactly. And the probes we
use are universal—one pool of probes for
each of the five positions, and we never
change that, so it is simple.
Gitschier: So, you wash off the ligase
and remove the excess of the probes, and
take an image.
Drmanac: Correct. After we have the
image, we strip off the whole complex,
getting back to the clean DNA for position
2. We use the same anchor oligonucleotide
again and the next pool.
Gitschier: So this really is a bit
different from the original concept you
had in 1988 for sequencing by hybridiza-
tion, where you had a stretch of DNA and
you add a pool of labeled oligos to
interrogate a complete six-base sequence,
for example.
Drmanac: Yes, for all 4,096 possible
hexamers, for example, I have to test
4,096 probes—if I have four colors, I can
get down to about 1,000 tests, or 1,000
cycles.
Actually there was a paper published in
Nature Biotechnology—I was so happy to see
it—in 2008, and I cited it. They did
exactly that. They used five-base probes
and did 1,000 cycles and read the bacterial
genome with 1,000 cycles.
Gitschier: OK, let’s talk about how
Complete Genomics got started. You had
been working at Callida, a spin-off from
Hyseq.
Drmanac: First, I met John Curson,
our CFO and one of the three co-
founders, whose son worked at Callida.
John introduced me to Cliff Reid, our
CEO. Cliff was interested in starting up a
biotech company, so he called me. After
founding multiple enterprise software
startups, he decided to go into biotech.
He went back to MIT to learn molecular
biology. We licensed the IP [intellectual
property] from Callida for genome se-
quencing—this is a typical VC [venture
capital] approach. Companies have to be
focused; otherwise they won’t succeed. We
decided to license the technology specific
for that field.
In 2006, we got the first round of
funding for $6 million. [That was] the
birth of Complete Genomics. Twenty
years of experience in these different
technologies, and also IP, were very
important to shorten our development
time. That was a surprise, actually. Cliff
was so successful in getting funding that we
didn’t need public awareness. We were in
stealth mode for about three years. We
had already sequenced the first human
genome before we announced our exis-
tence.
Gitschier: What genome was it?
Drmanac: It was one of the HapMap
cell lines. We decided not to go with a
famous person. We just chose scientifically.
We were so focused. And one important
thing: we decided we were not going to
sequence a bacterial genome as a demon-
stration, not to focus on a thousand times
smaller scale. We knew the process
worked. It’s not a new chemistry or new
physics—it’s all about scale. We decided to
wait and sequence our first human ge-
nome. And I think we saved a year in
development because we focused on that
scale.
Gitschier: Why did you develop the
idea that it would always be a ‘‘complete’’
sequence?
Drmanac: That was the sole focus
from day one because that was what was
missing. You can use existing technologies
to sequence more species, but there was no
way to sequence hundreds of thousands of
human genomes.
If you are developing technology that is
universal, you always compromise. Flexi-
bility would be more important than
capacity and cost. But if you focus on
only the human genome, then you focus
on scale and cost rather than flexibility.
And that paid off. For example, our
production instrument can sequence 18
genomes in one run. And a run is about 11
days. Two terabases per run.
It’s a big project. Even today we’re not
doing the scale that we need to do to
understand a disease. If we take one type
of tumor—100 pairs of sequences from the
same type of tumor [tumor and normal
tissue from each patient]—then we will
know real pathways. We will have soon a
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50,000 mutations. So to figure something
out, you have to do 100 pairs. We want to
do 1 million genomes for research.
Gitschier: How many have you done
so far?
Drmanac: Last year, we delivered 50
to our partners. We just published a paper
with Lee Hood—two parents and two
children with Miller syndrome and a lung
disease similar to CF [cystic fibrosis]. And
they found genes causing both diseases—
compound heterozygotes in both cases.
Of course, having the parents helps you
confirm the findings, since there are new
mutations and sequencing errors. Our
accuracy is one of the best in the industry,
but still, there are tens of thousands of
errors, because our genome is so big. One
error in 200,000, but there are 3 billion
bases. So we can remove 75% of errors by
comparing parents and kids. They took
the 20,000 errors they thought they had
and tested them and found that 100 were
actually not sequencing errors, but de
novo mutations.
Gitschier: OK. Let’s finish up with
the beginning. You were born in Serbia,
which was then part of Yugoslavia.
Drmanac: Yes. Actually I was born in
1957, on December 25th, in a little village,
but my grandma hid me until 1958. She
didn’t want me to be the youngest in
school and in the army, because she
thought it would be a disadvantage
[because you are enrolled and enlisted
based on the calendar year of your birth],
so she made my official birth date January
2nd, 1958. That’s what is on my birth
certificate. It was a little village, so it was
possible to do this.
Having a grandma around is great for
kids. I had a nice long childhood in my
village, always playing outside or helping
with farm work. We were producing
almost all our food; we were buying just
a few things. We had to do many different
things successfully; otherwise, we would
not have enough food to eat.
When it became time to go to school,
my father was working in the city, about
four miles away, and I went to school in
the city with him to get a better education.
I walked down the hill and up the hill
every school day for 12 years.
My great-grandma never had an edu-
cation, she couldn’t read or write, but she
was very wise. She was consulted by many
people in the village about the calendar or
the moon, and somehow she knew every-
thing. She influenced me that you don’t go
to school so that you can get work—
anybody can get work. You go to school to
discover something or to invent something new!
Gitschier: Ah, it all started with that
very wise old lady! Tell me when the idea
of sequencing by hybridization took hold?
Drmanac: I was a graduate student at
the University of Belgrade and Kary
Mullis had just invented PCR. I think this
discovery is so important they should give
him two Nobel prizes! I was telling a new
member of our team about PCR and how
we could use it for whole-genome map-
ping. And at that moment I realized that if
we had all possible primers of a given
length, we could do sequencing. I imme-
diately became obsessed with this idea of
sequencing the entire genome at once
without using gel sequencing. I couldn’t
think about anything else. I would take my
children to the park—I have twins, a boy
and a girl—and so many times they would
deliberately ask me a question to which I
was supposed to answer ‘‘no’’ and I would
automatically say ‘‘yes.’’ And they would
say, ‘‘Dad, you are not listening to us, you
were supposed to answer ‘‘no’’ on this
question.’’ I am so thankful that my wife
was able to cope with me. She turned from
a medical doctor into a molecular biolo-
gist, on her own insistence, and we have
worked together ever since.
I’d like to tell you this. The SBH paper
got rejected by PNAS, Nature, NAR, and
maybe a few other journals. Theories of
biochemical methods were not valued at
that time. But my career depended on it.
Finally, thanks to Victor McKusick, it got
published in Genomics. He recognized the
value of large-scale human genome se-
quencing. I met him several years later
and thanked him for saving my career.
Gitschier: Then for a post-doc you
moved to Hans Lehrach’s lab in London,
again working on oligo hybridization. Was
it a bit of a culture shock to move to
London?
Drmanac: That is interesting. You
know, Yugoslavia was a communist coun-
try, and people think we were very limited.
But that wasn’t true. We had a lot of
influence from the West: foreign aid and
investment to prevent Russian expansion
in Yugoslavia and good lab equipment. In
1988, we got a US Department of Energy
genome program grant: 150,000 real
green US dollars to work on SBH. Quite
interesting—a US government depart-
ment that develops atomic bombs was
funding biotech research in a communist
country.
There were many cultural opportuni-
ties, education was good, and people had
jobs. The only off-limits thing was politics.
We did not have a multiparty system. If
you disagreed in politics, you could end up
in jail or get shot. But other than that, it
was really good. I didn’t care about
politics.
So when I went to London, I saw that
we had better equipment and laboratories
in Belgrade than in London. And I had
majored in Molecular Biology—they
didn’t have such a major in England.
They were bound by a long tradition, but
we in Belgrade weren’t. We had the
opportunity to do something new.
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